FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
America Forever Bytes
Vertex Pharmaceuticals · AFBytes
Company
Vertex Pharmaceuticals
Recent coverage
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
Vertex (VRTX) Announces Health Canada Acceptance of NDS for Suzetrigine
On May 21, 2026, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Health Canada accepted for review a New Drug Submission for suzetrigine for the treatment o...